This week on #AntibodyHour 🕙:. Our colleague Brian Elliott, VP, Clinical Lead and former oncologist shares his perspective on the innovation behind our antibody medicines and how at Genmab we are driven by a patient-first mindset and collaborative spirit. Watch below to learn

We want to hear from you! Please participate in the below poll: . What type of content would you like to see more from Genmab on X?.

It’s #NationalInternDay, and we want to thank our passionate summer interns in the Netherlands and the U.S. for their contributions at Genmab in helping advance innovation in antibody medicines, and we also reflect on our own internships and recognize those who came before us and

During this edition of #AntibodyHour 🕙:. Our colleague Shawn Keogan PhD, Director of Patient Advocacy, shares why embedding the patient perspective isn’t just good practice; it’s essential. At Genmab, we’re genuinely listening to patients and absorbing their insights - because

Inspiring Tomorrow's Scientists. Genmab is proud to nurture the next generation of scientific innovators. We partnered with @Students2Science to host aspiring scientists at our Princeton NJ location for a hands-on Exploration Day to inspire a passion for innovation. Learn more:

#ICYMI: We believe that transforming the lives of patients starts with empowering our people. This week on #AntibodyHour 🕙, hear from our colleagues Ewan Robson & Francis Blokzijl who share how our open culture drives collaboration to continue advancing innovation in antibody

Scientific #innovation powers our progress—from our deep expertise in antibody therapies to how we advance our late-stage pipeline. At Genmab, our approach to disease biology is grounded in purpose, and our R&D teams are fueled by deep curiosity and bold thinking. Dive deeper

After 23 incredible years, EVP & Chief Legal Officer Birgitte Stephensen will retire. We thank her for her lasting impact on our organization, culture, and people. We welcome Greg Mueller as our new EVP, General Counsel & Chief Legal Officer. Greg joins from AstraZeneca with

🎉 We’re thrilled to announce the grand opening of our expanded site in New Jersey, a vibrant space built for innovation, collaboration & our #OneGenmab spirit. We’re grateful to mark this moment with patient advisors, community leaders, government officials, academic partners,

This #CancerImmunotherapyMonth, meet our colleague Marieke Heineke, Senior Scientist at Genmab who explores novel immune mechanisms and helps translate early research into potential new antibody medicines. At Genmab, we’re advancing antibody therapies with the goal of

We believe that transforming the lives of patients starts with empowering our people. This week on #AntibodyHour 🕙, hear from our colleagues Ewan Robson & Francis Blokzijl who share how our open culture drives collaboration to continue advancing innovation in antibody

We’re looking forward to #18ICML, where we will be presenting 27 abstracts that showcase our latest research in #BloodCancer.

Leaving #EHA2025 inspired! Grateful to the @EHA_Hematology community for a powerful few days of science, collaboration, and innovation in hematology. A fantastic opportunity to connect, learn, and advance care for patients worldwide. #Innovation #Hematology

Breaking News: We shared new data evaluating our investigational antibody medicine in patients with relapsed or refractory #DLBCL at #EHA2025, in partnership with @AbbVie. Read more:

At #EHA2025, we are excited to present new clinical data for #BloodCancer. Swipe to learn more about the subtypes of non-Hodgkin #lymphoma (NHL) – a diverse group of blood cancers that arise from lymphocytes, a type of white blood cell.

#InvestorUpdate: We are excited to participate in a fireside chat at the @GoldmanSachs 46th Annual Global Healthcare Conference. Click here to learn more:

We’re excited to share the latest from our #hematology research at #EHA25! Join us at the European Hematology Association’s Congress to explore how we’re turning science into medicine. Visit us at location G.03 and learn more here: #Oncology #Biotech

Thank you to everyone who connected with us at the @ASCO 2025 meeting! We're energized by the conversations, inspired by the community, and proud to share our purpose in advancing cancer care. #ASCO2025 #Oncology #Innovation

On this #NationalCancerSurvivorsDay we’re spotlighting the voices that matter most — patients. Hear from Keith & Portia as they share their powerful journeys and survivorship. #PatientFirst #Innovation

We’re headed to #BIO2025 and ready to connect, collaborate, and drive antibody innovation forward. For more information, please contact licensing@genmab.com. #BIOInternationalConvention #Biotech